quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:45:50·162d
SECFiling
Atea Pharmaceuticals Inc. logo

SEC Form 10-Q filed by Atea Pharmaceuticals Inc.

AVIR· Atea Pharmaceuticals Inc.
Health Care
Full content unavailable. See the original source below.
Original source

Companies

  • AVIR
    Atea Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Aug 13UpdateMorgan Stanley$6.88
  • Aug 10UpdateJP Morgan-
  • Mar 2UpdateJP Morgan$8.00
  • Mar 1UpdateSVB Leerink$9.00
  • Feb 16UpdateSVB Leerink$10.00
  • Jan 6UpdateMorgan Stanley$7.00

Related

  • SEC28d
    Amendment: SEC Form SCHEDULE 13G/A filed by Atea Pharmaceuticals Inc.
  • PR31d
    ReAlta Life Sciences Appoints Howard Berman, Ph.D., as CEO and Kia Motesharei, Ph.D., as President and COO
  • INSIDER41d
    Officer Corcoran Andrea exercised 60,000 shares at a strike of $1.24, increasing direct ownership by 8% to 823,576 units (SEC Form 4)
  • SEC49d
    SEC Form 10-K filed by Atea Pharmaceuticals Inc.
  • SEC49d
    Atea Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
  • PR49d
    Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
  • PR57d
    Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026
  • PR59d
    Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022